148 related articles for article (PubMed ID: 15962840)
1. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines.
Specchia G; Buquicchio C; Pansini N; Di Serio F; Liso V; Pastore D; Greco G; Ciuffreda L; Mestice A; Liso A
J Lab Clin Med; 2005 Apr; 145(4):212-20. PubMed ID: 15962840
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines.
Mort MK; Sen JM; Morris AL; DeGregory KA; McLoughlin EM; Mort JF; Dunn SP; Abuannadi M; Keng MK
J Oncol Pharm Pract; 2020 Apr; 26(3):680-687. PubMed ID: 31500517
[TBL] [Abstract][Full Text] [Related]
4. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
[TBL] [Abstract][Full Text] [Related]
5. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.
Jones M; O'Gorman P; Kelly C; Mahon N; Fitzgibbon MC
Ann Clin Biochem; 2017 Jan; 54(1):149-157. PubMed ID: 27170025
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
7. The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up.
Oztarhan K; Guler S; Aktas B; Arslan M; Salcioglu Z; Aydogan G
Pediatr Hematol Oncol; 2011 Aug; 28(5):380-94. PubMed ID: 21699467
[TBL] [Abstract][Full Text] [Related]
8. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
[TBL] [Abstract][Full Text] [Related]
9. Early prediction of anthracycline induced cardiotoxicity.
Erkus B; Demirtas S; Yarpuzlu AA; Can M; Genc Y; Karaca L
Acta Paediatr; 2007 Apr; 96(4):506-9. PubMed ID: 17391467
[TBL] [Abstract][Full Text] [Related]
10. Late cardiotoxicity of anthracyclines in children with acute leukemia.
Zalewska-Szewczyk B; Lipiec J; Bodalski J
Klin Padiatr; 1999; 211(4):356-9. PubMed ID: 10472576
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity evaluation in pediatric patients with acute lymphoblastic leukemia - results of prospective study.
Radu LE; Ghiorghiu I; Oprescu A; Dorobantu D; Arion C; Colita A
Med Ultrason; 2019 Nov; 21(4):449-455. PubMed ID: 31765454
[TBL] [Abstract][Full Text] [Related]
12. Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines.
Ylänen K; Poutanen T; Savukoski T; Eerola A; Vettenranta K
Acta Paediatr; 2015 Mar; 104(3):313-9. PubMed ID: 25393922
[TBL] [Abstract][Full Text] [Related]
13. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
[TBL] [Abstract][Full Text] [Related]
14. Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia.
Horacek JM; Jebavy L; Vasatova M; Pudil R; Tichy M; Jakl M; Maly J
Bratisl Lek Listy; 2013; 114(12):708-10. PubMed ID: 24329509
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review.
Hefti E; Blanco JG
Cardiovasc Toxicol; 2016 Jan; 16(1):5-13. PubMed ID: 25616318
[TBL] [Abstract][Full Text] [Related]
16. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
17. [Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].
Lemez P; Stejskal J; Cahová S; Holub M; Svítil P; Maresová J; Vásová I; Boudová L; Benesová V; Dvoráková D; Fisar J; Slavícek L
Vnitr Lek; 2004 Jun; 50(6):438-46. PubMed ID: 15346637
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors].
Benvenuto GM; La Vecchia L; Morandi P; Ruffini P; Mezzena G
Ital Heart J Suppl; 2000 Nov; 1(11):1457-63. PubMed ID: 11109196
[TBL] [Abstract][Full Text] [Related]
19. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
[TBL] [Abstract][Full Text] [Related]
20. [Noninvasive evaluation of chronic cumulative and acute cardiotoxicity induced by anthracycline in children with acute leukemia. Assessment of mainly left ventricular contractile state by M mode echocardiography].
Nakada S; Ogawa S; Hirayama T
Nihon Ika Daigaku Zasshi; 1994 Jun; 61(3):209-19. PubMed ID: 8045995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
